Pharmaceuticals & Therapeutics

Investors and patients await Puma Bio's Q4 results, focusing on NERLYNX sales performance and crucial updates on its promising alisertib cancer pipeline.

With a promising heart failure drug in trials, the biotech aims to woo investors at the Oppenheimer conference to fund its attack on age-related diseases.

DifGen Pharmaceuticals' new FDA-approved generic eye drop is only the second of its kind, promising to increase competition and lower costs for patients.

Helsinki pioneers a revolutionary cancer therapy, offering new hope with a targeted neutron beam that destroys tumors in just one or two sessions.

In a landmark move, the FDA has removed major risk warnings from hormone therapy drugs, signaling a new era for women's health after decades of fear.

A new plant-derived drug shows promise in preventing prostate cancer and improving cholesterol, but the company faces significant financial hurdles ahead.

The Norwegian drugmaker posted all-time high revenue and EBITDA for 2025, signaling resilience and a strategic pivot to future growth beyond metformin.

Nektar Therapeutics secures a massive $400M offering, signaling strong investor faith in its lead drug, rezpegaldesleukin, for autoimmune diseases.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

A 'world-first' cervical implant from Zavation Medical Products combines two materials to enhance bone growth while maintaining critical imaging capabilities.

Amid a record backlog and major program milestones, CEO Kathy Warden is set to detail the defense giant's strategy at Citi's upcoming tech and mobility event.

Australian biotech Amplia Therapeutics is bringing its promising pancreatic cancer trial to the US, a key step in developing a drug that targets the disease's defenses.

After a decade-long battle with Stage 4 cancer, one patient's cure spotlights a revolutionary immunotherapy and its potential to change cancer treatment.

Radiation tech giant Mirion appoints three new executives, signaling a major strategic push into next-gen nuclear, advanced cancer care, and AI.

A new partnership with Uniphar will use managed access programs to provide the lymphoma therapy LYMPHIR to European patients with limited treatment options.

Amid a surging aerospace market, StandardAero's upcoming earnings report is highly anticipated after a year of record growth and strategic expansion.

As OneSpaWorld prepares its Q4 results, all eyes are on the wellness giant as a barometer for luxury travel spending and its tech-driven future.

NervGen Pharma to unveil data showing its drug NVG-291 provides lasting functional gains for chronic spinal cord injury, a major step forward.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.

South Korea's Hugel shatters sales records with a 105% surge in the Americas, signaling a major power shift in the global medical aesthetics market.